Conferences - Results from #20

Viewing 21-40 of 11745 articles

ASTRO 2024: Pathologic Features of Small Cell Variants of the Genitourinary Tract

ASTRO 2024: Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer: Final Analysis of a Phase 2 Trial

ASTRO 2024: Hypofractionated, Dose-Escalated Radiation vs. Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase 3, Prospective, Randomized Controlled Trial

ASTRO 2024: Pembrolizumab Monotherapy Following Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer

ASTRO 2024: Bi-Institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer

ASTRO 2024: Natural History after Likely Cure versus Recurrence after ProsTate RadiOtheRapy (RAPTOR): A Pooled Analysis of More than 13000 Patients from 21 Randomized Controlled Trials

ASTRO 2024: Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Localized Prostate Cancer

ASTRO 2024: Role of Brachytherapy for Unfavorable Intermediate Risk Prostate Cancer

ASTRO 2024: Long-Term Patient-reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial

ASTRO 2024: Prospective Evaluation of Supplemental External Beam Radiotherapy in Higher Risk Prostate Cancer Patients Implanted with Pd-103: Long-Term Results of the 44/20/0 Trials

ASTRO 2024: Randomized Controlled Trial of PSMA-PET Image Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: Which Patients Are Most Likely to Benefit and Other Secondary Analyses

ASTRO 2024: Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer

ASTRO 2024: A Randomized Comparison of Low Dose Rate or High Dose Rate Brachytherapy Combined with External Beam Radiation for Unfavorable Intermediate or High-risk Prostate Cancer: Efficacy Results at Median 6 Years

ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate Cancer

ASTRO 2024: Role of ADT and Genomic Risk Stratification for Patients with Unfavorable Intermediate-Risk Prostate Cancer

ASTRO 2024: Strategies and Evidence for SABR in RCC

ASTRO 2024: Bladder Cancer - The Dawn or Era of More Personalized Radiotherapy

ASTRO 2024: Integrating Novel Therapeutics with Trimodal Therapy (TMT)

ASTRO 2024: Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicenter Randomized Controlled Trial

ASTRO 2024: Short-Term Androgen Deprivation Therapy and High-Dose Radiotherapy in Intermediate- and High-Risk Localized Prostate Cancer: Results from the GETUG 14 Randomized Phase III Trial

1
2
3
4
5
6
7
8
9
10